1. National Comprehensive Cancer Network;Clinical practice guidelines in oncology. Genetic/familial high risk assessment: breast and ovarian,2019
2. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer;Markman;Women’s Health (Lond),2018